← Eichor
Condition: Lazertinib Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Lazertinib

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy
Phase 2 · 1 location(s) · Konkuk University Medical Center · NCT05469022A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, f
Phase 2 · 202 location(s) · Janssen Research & Development, LLC · NCT06667076Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment
Phase 2 · 1 location(s) · Samsung Medical Center · NCT06106802A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated N
Phase 2 · 1 location(s) · Janssen Research & Development, LLC · NCT07586202A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker
Phase 2 · 5 location(s) · National Cancer Center, Korea · NCT06156527
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.